Title
.png)
Meet Our Guest Speaker
Dr. Michael Mendoza is the 9th Commissioner of Public Health for Monroe County. He is also appointed as Associate Professor at the University of Rochester in the Departments of Family Medicine, Public Health Sciences, and Nursing.
Dr. Mendoza joined the Health Department in 2016. As Commissioner of Public Health, Dr. Mendoza’s vision is to improve population health by strengthening the collaboration between clinical medicine and public health in our community. He has a particular focus on addressing the disparities in health and health care here in Monroe County. In this role, he oversees the health department’s $61 million budget and over 250 employees whose responsibilities span a diverse array of services designed to preserve and improve public health in Monroe County.
Prior to 2016, Dr. Mendoza served as Medical Director for Highland Family Medicine, one of the largest family medicine training practices in the country. During his seven years in this role, Dr. Mendoza oversaw the adoption of the Epic EMR, Meaningful Use, certification as a Level 3 Patient-Centered Medical
Home, and helped to lay the foundation for expanded team-based care, the
current expansion of HFM, and the newly certified Nurse Practitioner residency program.
Board-certified in family medicine, Dr. Mendoza continues to see patients as a primary care physician at Highland Family Medicine, and he continues to serve as a teaching physician on the inpatient service at Highland Hospital.
He received his medical degree from the University of Chicago, his Masters in Public Health from the University of Illinois, his Masters in Business Administration from the Simon Business School at the University of Rochester, and his undergraduate degree in environmental studies also from the University of Chicago. He completed his graduate medical training at the University of California-San Francisco and served an additional year as Chief Resident at the San Francisco General Hospital.
He is an active member of the Rochester community, serving on the Boards of Directors of Willow Domestic Violence of Rochester, Common Ground Health, and the Rochester RHIO.
In his spare time, Dr. Mendoza enjoys spending time with his wife, two children, and their two miniature Goldendoodles. His hobbies include running, cycling, and cooking.
current expansion of HFM, and the newly certified Nurse Practitioner residency program.
Board-certified in family medicine, Dr. Mendoza continues to see patients as a primary care physician at Highland Family Medicine, and he continues to serve as a teaching physician on the inpatient service at Highland Hospital.
He received his medical degree from the University of Chicago, his Masters in Public Health from the University of Illinois, his Masters in Business Administration from the Simon Business School at the University of Rochester, and his undergraduate degree in environmental studies also from the University of Chicago. He completed his graduate medical training at the University of California-San Francisco and served an additional year as Chief Resident at the San Francisco General Hospital.
He is an active member of the Rochester community, serving on the Boards of Directors of Willow Domestic Violence of Rochester, Common Ground Health, and the Rochester RHIO.
In his spare time, Dr. Mendoza enjoys spending time with his wife, two children, and their two miniature Goldendoodles. His hobbies include running, cycling, and cooking.
Resident Abstracts
Click the name of each resident to read their full abstract.
Once all residents have presented, help our judges decide who should win the First Prize 2021 Lund Award for Resident Research by selecting your choice from the below dropdown menu and then hitting the "Vote" button.
Hover over each resident's picture to see their presentation title, or click to read their full abstract.
Once all residents have presented, help our judges decide who should win the First Prize 2021 Lund Award for Resident Research by selecting your choice from the below dropdown menu and then hitting the "Vote" button.
Preterm Prelabor Rupture of Membranes: Outcomes with Expectant Management until 35 versus 36 weeks
ALYSSA ADKINS, MD
Overnight Melatonin Concentration and Sleep Quality are Associated with Clinical Features of Polycystic Ovary Syndrome
ADAM EVANS, MD
Immediate Postplacental IUD Placement: Expulsion and Associated Risk Factors
EMILY LEUBNER, MD
Exploring timing of surgical abortion in women who use drugs
MIRIAM MCQUADE, MD
Preterm Prelabor Rupture of Membranes: Outcomes with Expectant Management until 35 versus 36 weeks
Alyssa Adkins, Aaron Dom, Tara Lynch, Courtney Olson-Chen
Objective: The optimal gestational age for delivery after preterm prelabor rupture of membranes (PPROM) is unclear. Our objective was to evaluate the outcomes of expectant management of PPROM until 36 weeks versus immediate delivery at 35 weeks.
Methods: This was a single center retrospectivecohort study. Patients with singleton pregnancies admitted with PPROM > 20 weeks from 1/1/2011 to 11/1/2019 were studied. Groups were defined as expectant management until 36 weeks versus immediate delivery at 35 weeks. Importantly, the hospital guideline for management of PPROM extended expectant management to 36 weeks starting in 2017. Pregnancies with fetal abnormalities (karyotypeor major anatomic defects), multiple gestationsandchorioamnionitis or sepsis on admission were excluded. The primary outcome was composite neonatal morbidity: need for respiratory support, culture positive neonatal sepsis or antibiotic administration for > 72 hours. Secondary outcomes included need for NICU admission, length of NICU stay and maternal infection. Univariate analyses for categorical and continuous outcomeswere performed.
Results: A total of 187 mother-infant dyads were included in the study-51 (27.3%) were managed expectantly with a plan for delivery at 36 weeks and 136 (72.7%) were managed immediate delivery at 35 weeks. There was no significant difference in the composite neonatal outcome when comparing immediate delivery at 35 vs expectant management until 36 weeks (44.9% vs 29.4%, p=0.056, OR = 1.95, 95% CI 0.98 to 3.86). Those with immediate delivery at 35 weeks had a 3.9 times increased risk of NICU admission (OR 3.9, 95% CI 1.6, 9.5). They also had a longer NICU length of stay (mean of 7.8 days versus 4 days, p<0.001). There was no difference in maternal chorioamnionitis or endometritis between the two groups.
Conclusion: This study found no difference in composite neonatal morbidity whenPPROM was managed expectantly until 36 weeks as compared to immediate delivery at 35 weeks. Additionally, those managed until 36 weeks had a decreased risk of NICU admission and shorter NICU stay when compared to those delivered at 35 weeks.
Characterization and comparison of pelvic mass risk assessment by gynecologists and PCP’s to ROMA.
ALEXANDRA MORELL, MD
LAUREN PARAISON, MD
Racial representation in obstetric guidelines: A focus on hypertensive disorders during and before pregnancy
Experiences of Women at Crisis Pregnancy Centers in Western New York